Novel Drugs and Devices to Lower Intraocular Pressure Market, by Treatment Type (Drug (Rhopressa, Roclatan, Xelpros, Vyzulta and Others) and Device (Implant, Therapeutic Ultrasound and Others), by Distribution Channel (Hospitals & Clinics, Retail Channel and Online Channels), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2019 – 2027

  • To Be Published : Nov 2019 |
  • Format : CMI Insight PPT Format CMI Insight PDF Format

Intraocular pressure is the pressure present inside the eye. The aqueous humour of the ciliary body in the eye is responsible for the intraocular pressure. The production and removal rate of aqueous humour by the ciliary body determines the pressure in the eye. The presence of extra fluid (aqueous humour) builds up pressure in the eye which can lead to glaucoma. There are two types of glaucoma, open–angle glaucoma and closed–angle glaucoma. Generally, tonometers are used for determining the pressure present in the eye.

Global Novel Drugs and Devices to Lower Intraocular Pressure Market Drivers

Approvals of drugs and devices associated with the treatment of glaucoma from regulatory bodies is expected to boost the global novel drugs and devices to lower intraocular pressure market growth. For instance, in May 2019, Ivantis Inc., received an approval from the U.S. Food and Drug Administration (FDA) for Hydrus microstent. It is a device used in minimally invasive glaucoma surgery. It is developed to lower eye pressure in patients with open angle glaucoma.

Furthermore, in September 2018, Sun Pharmaceuticals Industries Ltd. received an approval from U.S. FDA for Xelpros (latanoprost ophthalmic emulsion) for treatment of glaucoma. It reduces the elevated intraocular pressure in the eye and has been designed with the help of Swollen Micelle Micro emulsion technology. Frequent approvals of drugs and devices is expected to accelerate global novel drugs and devices to lower intraocular pressure market growth.

Key players are focused on monitoring post marketing results of approved drugs and devices for the treatment of glaucoma (Intraocular pressure), which is expected to drive the global novel drugs and devices to lower intraocular pressure market growth. For instance, Rhopressa drug manufactured by Aerie Pharmaceuticals was originally approved in December 2017 by U.S. Food and Drug Administration (FDA). The company is now studying the Rhopressa drug (Netarsudil ophthalmic solution) for its pharmacovigilance studies. The drug is being studied for its long-term effects on patients with open angle glaucoma and ocular hypertension. The study is expected to be completed by September 2019. Such developments are expected to drive the global novel drugs and devices to lower intraocular pressure market growth.

Global Novel Drugs and Devices to Lower Intraocular Pressure Market Regional Analysis

North America is expected to be dominant in global novel drugs and devices to lower intraocular pressure market during the forecast period. Factors such as government initiatives expected to augment the North America novel drugs and devices to lower intraocular pressure market growth. For instance, in January 2019, Glaucoma Research Foundation, U.S., formed a team called Catalyst for a Cure. The investigators are working together to understand the exact cause of vision loss in glaucoma patients, and potential targeted therapies for the prevention and treatment of glaucoma. As a result, this factor is expected to support the global novel drugs and devices to lower intraocular pressure market growth.

Global Novel Drugs and Devices to Lower Intraocular Pressure Market Restraints

Side effects of glaucoma medications are expected to hinder growth of the global novel drugs and devices to lower intraocular pressure market. Side effects of medications used for the treatment of glaucoma, such as Rhopressa, include internal bleeding, corneal deposits, and stinging. Also, the cost of these medications is very high. For instance, 2.5 milliliter’s of Rhopressa (Netarsudil ophthalmic solution) costs around US$269. Hence, these factors are expected to restrain the global novel drugs and devices to lower intraocular pressure market growth.

Global Novel Drugs and Devices to Lower Intraocular Pressure Market Key Players

Some of the major players operating in the global novel drugs and devices to lower intraocular pressure market include, Mati Therapeutics Inc, BioLight Lifesciences Ltd., IOPtima Ltd., Eye Sonix, Bausch & Lomb Inc., Sun Pharmaceutical Industries Ltd., Allergan, Alcon Inc., Glaukos Corporation, and Pfizer Inc.

Global Novel Drugs and Devices to Lower Intraocular Pressure Market Taxonomy

The global novel drugs and devices to lower intraocular pressure market is segmented on the basis of treatment, distribution channel, and region.

By Treatment Type

  • Drugs
    • Rhopressa
    • Roclatan
    • Xelpros
    • Vyzulta
    • Others
  • Devices
  • Implant
  • Therapeutic Ultrasound
  • Others

By Distribution Channel

  • Hospitals & Clinics
  • Retail Channel
  • Online Channel

By Region

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.